Marc de Fromont

872 total citations
25 papers, 641 citations indexed

About

Marc de Fromont is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Epidemiology. According to data from OpenAlex, Marc de Fromont has authored 25 papers receiving a total of 641 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 13 papers in Molecular Biology and 4 papers in Epidemiology. Recurrent topics in Marc de Fromont's work include Renal cell carcinoma treatment (16 papers), Renal and related cancers (13 papers) and Cancer Genomics and Diagnostics (4 papers). Marc de Fromont is often cited by papers focused on Renal cell carcinoma treatment (16 papers), Renal and related cancers (13 papers) and Cancer Genomics and Diagnostics (4 papers). Marc de Fromont collaborates with scholars based in France and Luxembourg. Marc de Fromont's co-authors include Christian Coulange, É. Lechevallier, Laurent Daniel, D Brétheau, Marc André, Dominique Rossi, C. Eghazarian, Bernard Escudier, Hervé Lang and Alain Ravaud and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Radiology.

In The Last Decade

Marc de Fromont

24 papers receiving 626 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc de Fromont France	8	594	444	208	115	89	25	641
Farhood Alamdari Sweden	13	431 0.7×	355 0.8×	162 0.8×	232 2.0×	174 2.0×	29	669
Iori Sakai Japan	18	509 0.9×	177 0.4×	99 0.5×	239 2.1×	137 1.5×	48	708
Yasser Ged United States	12	361 0.6×	244 0.5×	169 0.8×	87 0.8×	212 2.4×	59	549
Thomas Schnoeller Germany	14	557 0.9×	147 0.3×	237 1.1×	209 1.8×	166 1.9×	23	791
Laura‐Maria Krabbe Germany	13	433 0.7×	122 0.3×	182 0.9×	221 1.9×	154 1.7×	46	651
Ikuo Kamiyama Japan	10	193 0.3×	81 0.2×	74 0.4×	48 0.4×	187 2.1×	29	413
Linda Feeley Ireland	14	71 0.1×	97 0.2×	163 0.8×	230 2.0×	291 3.3×	38	670
Muhammad Bulbul Lebanon	12	279 0.5×	101 0.2×	51 0.2×	212 1.8×	71 0.8×	52	481
Bonnie Choy United States	11	216 0.4×	127 0.3×	49 0.2×	140 1.2×	83 0.9×	35	462
Akihito Akiyama Japan	8	157 0.3×	180 0.4×	79 0.4×	52 0.5×	68 0.8×	13	355

Countries citing papers authored by Marc de Fromont

Since Specialization

Citations

This map shows the geographic impact of Marc de Fromont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc de Fromont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc de Fromont more than expected).

Fields of papers citing papers by Marc de Fromont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc de Fromont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc de Fromont. The network helps show where Marc de Fromont may publish in the future.

Co-authorship network of co-authors of Marc de Fromont

This figure shows the co-authorship network connecting the top 25 collaborators of Marc de Fromont. A scholar is included among the top collaborators of Marc de Fromont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc de Fromont. Marc de Fromont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravaud, Alain, Stéphane Oudard, Marc de Fromont, et al.. (2015). First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Annals of Oncology. 26(6). 1123–1128. 121 indexed citations

Ravaud, Alain, Stéphane Oudard, Marc de Fromont, et al.. (2012). First Line Sunitinib in Type I and II Papillary Renal Cell Carcinoma (PRCC): Supap- A Phase II Study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP). Annals of Oncology. 23. ix263–ix263. 7 indexed citations

Ravaud, Alain, Stéphane Oudard, Gwénaëlle Gravis, et al.. (2009). First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). Journal of Clinical Oncology. 27(15_suppl). 5146–5146. 27 indexed citations

Molinié, Vincent, Mathilde Sibony, Gaëlle Fromont, et al.. (2008). Fiche compte rendu standardisé et biopsies prostatiques.. Annales de Pathologie. 28(5).

Long, Jean‐Alexandre, Y. Neuzillet, Jean-Michel Corréas, et al.. (2008). Kystes atypiques et tumeurs kystiques du rein : considérations anatomopathologiques, radiologiques et chirurgicales. Conclusions du forum AFU 2007. Progrès en Urologie. 19(1). 8–14. 7 indexed citations

Cornu, Jean Nicolas, Morgan Rouprêt, H. Lang, et al.. (2008). Prise en charge du cancer du rein en 2007 : actualités et recommandations. Progrès en Urologie. 18. S81–S87. 12 indexed citations

Neuzillet, Y., Jean-Michel Corréas, Bernard Escudier, et al.. (2008). Quelle peut être la durée du délai entre le diagnostic et le traitement chirurgical du cancer du rein ?. Progrès en Urologie. 18(4). 197–203. 3 indexed citations

Valeri, Andrea, Hauke Lang, J Descotes, et al.. (2005). 185Pathological features of kidney masses 4 CM or less: The less frequently malignant nature compared to larger tumours, supports the interest of nephron sparing surgery. European Urology Supplements. 4(3). 49–49. 1 indexed citations

Neuzillet, Y., et al.. (2005). [Renal oncocytoma associated with renal cell carcinoma].. PubMed. 15(2). 312–4. 3 indexed citations

10.

Lang, Hervé, Véronique Lindner, Marc de Fromont, et al.. (2004). Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma. Cancer. 103(3). 625–629. 85 indexed citations

11.

Méjean, Arnaud, Marc André, J.-D. Doublet, et al.. (2004). [Kidney tumors].. PubMed. 14(4 Suppl 1). 997, 999–1035. 1 indexed citations

12.

Fromont, Marc de & Christian Coulange. (2004). Tumeurs rares du rein de l’adulte. Annales d Urologie. 38(1). 15–23. 4 indexed citations

13.

Fromont, Marc de. (2003). Tumeurs rares du rein de l'adulte. Annales d Urologie. 38(1). 15–23. 4 indexed citations

14.

Daniel, Laurent, É. Lechevallier, Roch Giorgi, et al.. (2001). CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas. The Journal of Pathology. 193(3). 345–349. 17 indexed citations

15.

Petit, Philippe, et al.. (2001). [Renal onococytic adenoma].. PubMed. 82(4). 455–61. 3 indexed citations

16.

Lechevallier, É., Marc André, Laurent Daniel, et al.. (2000). Fine-Needle Percutaneous Biopsy of Renal Masses with Helical CT Guidance. Radiology. 216(2). 506–510. 163 indexed citations

17.

Vieillefond, Annick, B Cochand‐Priollet, M C Dauge-Geffroy, et al.. (1999). Recommandations pratiques pour les prélèvements prostatiques. Les Membres du Sous-Comité Prostate du Comité de Cancerologie de l'Association Française d'Urologie.. Annales de Pathologie. 19(6). 2 indexed citations

18.

Daniel, Laurent, et al.. (1998). [Malignant Leydig cell tumor of the testis secreting progesterone].. PubMed. 8(6). 1047–50. 3 indexed citations

19.

Lechevallier, É., et al.. (1997). [Malignant histiocytofibroma of the bladder. A case report].. PubMed. 7(2). 270–2. 4 indexed citations

20.

Brétheau, D, et al.. (1995). Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 76(12). 2543–2549. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact